GRANULES INDIA LTD.-$ - 532482 - Board Meeting Outcome for Financial Results For The Quarter Ended On June 30, 2023
Financial Results for the quarter ended on June 30, 202309-08-2023
09-08-2023
GRANULES INDIA LTD.-$ - 532482 - Granules India Limited Received US FDA Approval For The ANDA Filed For Metoprolol Succinate ER Tablets
Granules India Limited received US FDA approval for the ANDA filed for Metoprolol Succinate ER Tablets08-08-2023
Granules Pharma clears US FDA inspection with zero observation; shares gain
This is Granules India's fourth FDA audit since March with zero observations.04-08-2023
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Earnings Conference call for Q1 of FY24.26-07-2023
GRANULES INDIA LTD.-$ - 532482 - Board Meeting Intimation for Consideration And Approval Of The Un-Audited Financial Results For The First Quarter Ended On June 30, 2023
GRANULES INDIA LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 ,inter alia, to consider and approve un-audited financial results for the first quarter ended on June 30, 202326-07-2023
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication20-07-2023
GRANULES INDIA LTD.-$ - 532482 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for FY 2022-2319-07-2023
GRANULES INDIA LTD.-$ - 532482 - Reg. 34 (1) Annual Report.
Annual Report for FY 2022-202319-07-2023
Granules India foreign subsidiary gets USFDA approval; stock price gains
This product will be launched through Granules Consumer Health (GCH) division.14-07-2023